# ChemComm

## COMMUNICATION

# The four-step total synthesis of (−)-chaetominine†

Qi-Long Peng,‡ Shi-Peng Luo,‡ Xiao-Er Xia, Liang-Xian Liu and Pei-Qiang Huang*

**The total synthesis of the alkaloid (−)-chaetominine (1) has been achieved in four steps with an overall yield of 33.4%. Key features of our strategy include a one-pot cascade indole epoxidation – epoxide ring-opening cyclization – lactamization reaction sequence, and the use of a nitro group as a latent amino group for the one-pot construction of the quinazolinone ring. This constitutes a step economical, redox economical and protecting group-free total synthesis.**

Efficiency is a major pursuit in organic synthesis, which is of particular importance in the field of the total synthesis of complex natural products.[1] With this end in view, the concepts of step economy,[2] pot economy,[3] redox economy,[4] and protecting group-free synthesis[5] have been introduced. Recently, a number of quite concise total syntheses have been achieved.[6]

In 2006, Tan and co-workers reported the isolation of a new alkaloid (−)-chaetominine (**1** in Fig. 1) from the solid-substrate culture of *Chaetomium* sp. IFB-E015, an endophytic fungus on apparently healthy *Adenophora axilliflora* leaves.[7] The intriguing structural feature in combination with the reported potent

activity against human leukemia K562 (21 nM) and colon cancer SW1116 (28 nM) cell lines[7] made (−)-chaetominine an attractive synthetic target.[8] Snider and co-workers reported the first total synthesis of (−)-chaetominine soon after its isolation.[8a] Later on, Evano and Papeo reported the second[8b] and the third approaches.[8c] Papeo's work also clarified that (−)-chaetominine (**1**) showed a negligible inhibitory activity on several cancer cell lines.[8c] The fourth one disclosed by Evano *et al.* has so far been the most efficient with nine steps and 14% overall yield from D-tryptophan.[8d]

With our interest in the asymmetric synthesis of bioactive natural products[9] and the development of step economical synthetic methodologies,[10] we envisaged that (−)-chaetominine (**1**) is an ideal molecule for demonstrating the concepts of step economy, pot economy, redox economy, and protecting group-free synthesis. We report herein a four-step total synthesis of (−)-chaetominine (**1**) starting from D-tryptophan.[11]

Our retrosynthetic analysis of (−)-chaetominine (**1**) is depicted in Scheme 1. The key feature of our approach resides in the ambitious one-pot formation of (−)-chaetominine (**1**) from



Fig. 1  Structure of (−)-chaetominine (**1**).

*Department of Chemistry and Fujian Provincial Key Laboratory for Chemical Biology, College of Chemistry & Chemical Engineering, Xiamen University, Xiamen, Fujian 361005, PR China. E-mail: pqhuang@xmu.edu.cn; Fax: +86-592-2189959*

† Electronic supplementary information (ESI) available: X-ray structures, experimental procedures and compound characterization data, and ^{1}H and ^{13}C NMR spectra of new compounds. CCDC 791762–791764 and 884128. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c3cc48833k

‡ These authors contributed equally to this work.



Scheme 1  Retrosynthetic analysis of (−)-chaetominine (**1**).

quinazolinonetripeptide **2** *via* a one-pot cascade indole epoxidation – epoxide ring-opening cyclization – lactamization reaction sequence. The formation of the pyrrolo[2,3-*b*]indole ring system through β-oxygenation of tryptophan derivatives followed by nucleophilic addition at the α-position has been known for a long time, which includes the photosensitized oxygenation,[12] and Witkop's stepwise oxidative transposition.[13] Recently, much attention has been paid to the oxidative cyclization of tryptophan derivatives,[14–16] due to the presence of the pyrrolo-[2,3-*b*]indole ring system in many bioactive alkaloids.[17] Nevertheless, to the best of our knowledge, no redox and protecting group-free oxidative cyclization leading to the fused six-membered ring system (piperidino[2,3-*b*]indole) has ever been reported.[12–17] Even in the cases where formation of both five or six-membered rings was possible, the five-membered ring product (pyrrolo[2,3-*b*]indole) always dominated over the six-membered ring.[14b,d] In the first total synthesis of kapakahines B and F,[14b,c] Baran and co-workers have developed an elegant method for the access to the tetrahydro-1*H*-pyrido[2,3-*b*]indole ring system of kapakahines by *in situ* kinetic trapping of a dynamic mixture.

Thus construction of the tricyclic core of (−)-chaetominine (**1**) from the tryptophan derived dipeptide **2** *via* epoxidative cyclization appeared to be quite challenging. Nevertheless, considering the high efficiency of this approach, it was worthwhile to be engaged in this adventure.

As regards the quinazolinone ring system, a number of methods have been reported.[18] In view of developing a protecting group-free total synthesis of (−)-chaetominine (**1**), the nitro group was envisioned as a latent amino group for the construction of the quinazolinone ring. Thus *o*-nitrobenzoyl dipeptide derivative **3** was envisaged as the intermediate of our synthesis, which is readily accessible from commercially available D-tryptophan, *o*-nitrobenzoyl chloride, and L-alanine methyl ester hydrochloride salt.

Our synthesis started with the aroylation of D-tryptophan with *o*-nitrobenzoyl chloride (THF, 1 M NaOH, 0 °C, 2 h), which gave the aroylated product **4** in 90% yield (Scheme 2). Successive treatment of compound **4** with i-BuOCOCl/N-methylmorpholine (NMM, THF, −20 °C, 15 min) and the L-alanine methyl ester hydrochloride salt (THF, NMM, −20 °C, 8 h) produced the desired dipeptide derivative **3** in 91% yield. The quinazolinone ring system[18] was constructed by a modification of Shi's method.[19] In the event, **3** was treated with HC(OMe)$_3$ and low valent titanium generated *in situ* from TiCl$_4$ and Zn powders in THF at 0–5 °C, which gave the desired quinazolinone **2** in 97% yield without observable epimerization. Higher temperature reported by Shi and co-workers[19] led to substantial epimerization.

With compound **2** in hand, we then focused on the key epoxidation-initiated cascade reaction to construct the tricyclic core of (−)-chaetominine (**1**). Although treatment of dipeptide **2** with a solution of DMDO in acetone at −78 °C for up to 1 h led to complex products, the results implied that the epoxidation might have occurred, but the unstable epoxide intermediate failed to cyclize to give the desired product **1**. So, basic conditions were envisaged to be necessary to realize the cascade epoxidation-bis-cyclization reactions (Scheme 2). In view of the easy epimerization of our substrate (*vide supra*), weak basic conditions are preferred to avoid any epimerization during the cyclization. After considerable experimentation, it was found that a combination of DMDO with DMSO gave optimal results. In the event, dipeptide **2** was first treated with DMDO in acetone at −78 °C for 1 h, and then DMSO (CaH$_2$ dried) was added, and the mixture was stirred at rt for 2 days to give the desired chaetominine (**1**) in 42% yield, along with a small portion of its lactamization precursor **5** (3% yield) and an epimer of the latter (**6**) in 51% yield. The structure of (−)-chaetominine (**1**) was confirmed by single crystal X-ray analysis.[20] The physical {[α]$_D^{20}$ −49.7 (*c* 0.48, MeOH) lit. −48 (*c* 0.45, MeOH);[8a] −49.4 (*c* 0.26, MeOH);[8b,c] −47.9 (*c* 0.25, MeOH);[8d] −70 (*c* 0.48, MeOH)[7]} and spectral data of our synthetic (−)-chaetominine (**1**) are identical to those reported. The structure of compound **6** was tentatively deduced from its cyclized product **7** and the bromo derivative **8**, both determined



**Scheme 2** *Reagents and conditions*: (i) *o*-nitrobenzoyl chloride, 1 M NaOH, THF, 0 °C, 2 h; (ii) H-L-Ala-OMe·HCl, ClCO$_2$$^i$Bu, NMM, THF, −20 °C, 8 h; (iii) HC(OMe)$_3$, Zn/TiCl$_4$, THF, 0 °C, 1 day; (iv) DMDO, acetone, −78 °C, 1 h; then, DMSO (CaH$_2$ dried), rt, 48 h. Syntheses of compounds **7** and **8** for single crystal X-ray diffraction analysis: (v) NaOMe, MeOH, −10 °C, 90%; (vi) NBS, rt; NaOMe, MeOH, −10 °C, 40% (unoptimized).

by single crystal X-ray analysis.[20] The direct formation of chaetominine (1) from 2 implied that an *anti–cis* disposition between the hydroxyl group at C3 and the quinazolinonyl group favors the lactamization. For diastereomer 6, the fact that only in the presence of a base can the lactamization occur implied a *syn*-disposition between the substituents at C3 and C14.

It is worth mentioning that although the yield of chaetominine (1) from 2 *via* the epoxidation-trigged cascade reaction was modest, the strategy is highly efficient. In this cascade reaction sequence, three reactions have been accomplished in one-pot, which also avoided the use of any protecting group. In the previous syntheses,[8a–d] the highest diastereoselectivity (95% de) has been achieved with DMDO in Evano's first generation total synthesis of (−)-chaetominine (1).[8b] However, five steps were required to build the tricyclic ring system, which let them to abandon that route and develop a more efficient one.[8d]

In summary, we have disclosed a very concise and efficient strategy for the total synthesis of (−)-chaetominine (1) starting from D-Trp. This four-step total synthesis of (−)-chaetominine (1) has so far been the shortest one, with the highest overall yield of 33.4%.

## Notes and references

1  (*a*) B. M. Trost, *Science*, 1991, **254**, 1471–1477; (*b*) C.-J. Li and B. M. Trost, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 13197–13202.
2  (*a*) P. A. Wender, M. P. Croatt and B. Witulski, *Tetrahedron*, 2006, **62**, 7505–7511; (*b*) P. A. Wender, V. A. Verma, T. J. Paxton and T. H. Pillow, *Acc. Chem. Res.*, 2008, **41**, 40–49.
3  Three-pot total synthesis of prostaglandin PGE$_1$ methyl ester and PGA$_1$ methyl ester: Y. Hayashi and S. Umemiya, *Angew. Chem., Int. Ed.*, 2013, **52**, 3450–3452.
4  For a review, see: (*a*) N. Z. Burns, R. W. Hoffmann and P. S. Baran, *Angew. Chem., Int. Ed.*, 2009, **48**, 2854–2867; For an example, see: (*b*) J. M. Richter, Y. Ishihara, T. Masuda, B. W. Whitefield, T. Llamas, A. Pohjakallio and P. S. Baran, *J. Am. Chem. Soc.*, 2008, **130**, 17938–17954.
5  For reviews, see: (*a*) R. W. Hoffmann, *Synthesis*, 2006, 3531–3541; (*b*) I. S. Young and P. S. Baran, *Nat. Chem.*, 2009, **1**, 193–205; (*c*) R. Hili and A. K. Yudin, *Chem.–Eur. J.*, 2007, **13**, 6538–6542; For typical recent examples, see: (*d*) P. S. Baran, T. J. Maimone and J. M. Richter, *Nature*, 2007, **446**, 404–408; (*e*) V. Hickmann, M. Alcarazo and A. Fürstner, *J. Am. Chem. Soc.*, 2010, **132**, 11042–11044.
6  For selected examples, see: (*a*) three-pot total synthesis of (−)-oseltamivir: H. Ishikawa, T. Suzuki and Y. Hayashi, *Angew. Chem., Int. Ed.*, 2009, **48**, 1304–1307; (*b*) three-step synthesis of (−)-pycnanthuquinone C: F. Löbermann, P. Mayer and D. Trauner, *Angew. Chem., Int. Ed.*, 2010, **49**, 6199–6202; (*c*) four-step total synthesis of (±)-psychotrimine: A. Mendoza, Y. Ishihara and P. S. Baran, *Nat. Chem.*, 2012, **4**, 21–25; (*d*) seven-step total synthesis of prostaglandin PGF$_2$: G. Coulthard, W. Erb and V. Aggarwal, *Nature*, 2012, **489**, 278–281; (*e*) seven-step total synthesis of taxanes: T. Newhouse and P. S. Baran, *J. Am. Chem. Soc.*, 2008, **130**,

10886–10887; (*f*) eight-step total synthesis of (±)-stemoamide: Y. Wang, L. Zhu, Y. Zhang and R. Hong, *Angew. Chem., Int. Ed.*, 2011, **50**, 2787–2790.
7  R.-H. Jiao, S. Xu, J.-Y. Liu, H.-M. Ge, H. Ding, C. Xu, H.-L. Zhu and R.-X. Tan, *Org. Lett.*, 2006, **8**, 5709–5712.
8  (*a*) B. B. Snider and X.-X. Wu, *Org. Lett.*, 2007, **9**, 4913–4915; (*b*) M. Toumi, F. Couty, J. Marrot and G. Evano, *Org. Lett.*, 2008, **10**, 5027–5030; (*c*) B. Malgesini, B. Forte, D. Borghi, F. Quartieri, C. Gennari and G. Papeo, *Chem.–Eur. J.*, 2009, **15**, 7922–7929; (*d*) A. Coste, G. Karthikeyan, F. Couty and G. Evano, *Synthesis*, 2009, 2927–2934.
9  (*a*) S.-P. Luo, L.-D. Guo, L.-H. Gao, S. Li and P.-Q. Huang, *Chem.–Eur. J.*, 2013, **19**, 87–91; (*b*) H.-H. Huo, X.-E. Xia, H.-K. Zhang and P.-Q. Huang, *J. Org. Chem.*, 2013, **78**, 455–465.
10  (*a*) K.-J. Xiao, J.-M. Luo, K.-Y. Ye, Y. Wang and P.-Q. Huang, *Angew. Chem., Int. Ed.*, 2010, **49**, 3037–3040; (*b*) S.-H. Xiang, J. Xu, H.-Q. Yuan and P.-Q. Huang, *Synlett*, 2010, 1829–1832; (*c*) K.-J. Xiao, A.-E. Wang and P.-Q. Huang, *Angew. Chem., Int. Ed.*, 2012, **51**, 8314–8317; (*d*) K.-J. Xiao, A.-E. Wang, Y.-H. Huang and P.-Q. Huang, *Asian J. Org. Chem.*, 2012, **1**, 130–132; (*e*) K.-J. Xiao, A.-E. Wang, Y.-H. Huang and P.-Q. Huang, *Acta Chim. Sin.*, 2012, **70**, 1917–1922; (*f*) S.-Y. Huang, Z. Chang, S.-C. Tuo, L.-H. Gao, A.-E. Wang and P.-Q. Huang, *Chem. Commun.*, 2013, **49**, 7088–7090; (*g*) K.-J. Xiao, J.-M. Luo, X. E. Xia, Y. Wang and P.-Q. Huang, *Chem.–Eur. J.*, 2013, **19**, 13075–13086.
11  An application for a Chinese patent covering a part of this work was made by P.-Q. Huang, L.-X. Liu and Q.-L. Peng, ZL 200910110953.2, 2009, *in Chinese*, *Chem. Abstr.* CN20091110953 20090122.
12  (*a*) M. Nakagawa, S. Kato, S. Kataoka and T. Hino, *J. Am. Chem. Soc.*, 1979, **101**, 3136–3137; (*b*) M. Nakagawa, Y. Yokoyama, S. Kato and T. Hino, *Tetrahedron*, 1985, **41**, 2125–2132; (*c*) C. Didier, D. J. Critcher, N. D. Walshe, Y. Kojima, Y. Yamauchi and A. G. M. Barrett, *J. Org. Chem.*, 2004, **69**, 7875–7879.
13  M. Ohno, T. F. Spande and B. Witkop, *J. Am. Chem. Soc.*, 1968, **90**, 6521–6522.
14  (*a*) A. Mendoza, Y. Ishihara and P. S. Baran, *Nat. Chem.*, 2012, **4**, 21–25; (*b*) T. Newhouse, C. A. Lewis, K. J. Eastman and P. S. Baran, *J. Am. Chem. Soc.*, 2010, **132**, 7119–7137; (*c*) T. Newhouse, C. A. Lewis and P. S. Baran, *J. Am. Chem. Soc.*, 2009, **131**, 6360–6361; (*d*) T. Newhouse and P. S. Baran, *J. Am. Chem. Soc.*, 2008, **130**, 10886–10887; (*e*) P. S. Baran and J. M. Richter, *J. Am. Chem. Soc.*, 2004, **126**, 7450–7451.
15  (*a*) T. M. Kamenecka and S. J. Danishefsky, *Angew. Chem., Int. Ed.*, 1998, **37**, 2993–2995; (*b*) T. M. Kamenecka and S. J. Danishefsky, *Angew. Chem., Int. Ed.*, 1998, **37**, 2995–2998; (*c*) T. M. Kamenecka and S. J. Danishefsky, *Chem.–Eur. J.*, 2001, **7**, 41–63; (*d*) J. P. May, P. Fournier, J. Pellicelli, B. O. Patrick and D. M. Perrin, *J. Org. Chem.*, 2005, **70**, 8424–8430; (*e*) J. P. May, B. O. Patrick and D. M. Perrin, *Synlett*, 2006, 3403–3406.
16  (*a*) F. He, B. M. Foxman and B. B. Snider, *J. Am. Chem. Soc.*, 1998, **120**, 6417–6418; (*b*) D. Crich and X. H. Huang, *J. Org. Chem.*, 1999, **64**, 7218–7223; (*c*) R. Galli, M. Dobler, R. Güller, R. Stahl and H. J. Borschberg, *Helv. Chim. Acta*, 2002, **85**, 3400–3413; (*d*) S. V. Ley, E. Cleator and P. R. Hewitt, *Org. Biomol. Chem.*, 2003, **1**, 3492–3494.
17  For a recent review on natural products with hexahydropyrrolo-[2,3-*b*]indole, see: P. Ruiz-Sanchis, S. A. Savina, F. Albericio and M. Álvarez, *Chem.–Eur. J.*, 2011, **17**, 1388–1408.
18  For a review on quinazolinone alkaloids, see: S. B. Mhaske and N. P. Argade, *Tetrahedron*, 2006, **62**, 9787–9826.
19  (*a*) D.-Q. Shi, L.-C. Rong, J.-X. Wang, Q.-Y. Zhuang, X.-S. Wang and H.-W. Hu, *Tetrahedron Lett.*, 2003, **44**, 3199–3201; (*b*) D.-Q. Shi, X.-S. Wang, S.-J. Tu and H.-W. Hu, *Chin. J. Struct. Chem.*, 2003, **22**, 581–584; (*c*) D.-Q. Shi, J.-X. Wang, L.-C. Rong, Q.-Y. Zhuang and H.-W. Hu, *Chin. J. Chin. Univ.*, 2004, **25**, 462–465.
20  (*a*) (−)-chaetominine (1): CCDC 791762; (*b*) the precursor of (−)-chaetominine (compound 5): CDCC 791763; (*c*) compound 7: CCDC 791764; (*d*) compound 8: CCDC 884128. For single crystal X-ray structures, see: ESI†.